Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Option exercise triggers $25M payment to Pinetree. CAMBRIDGE, Mass., April 29, 2026 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree"), a biotechnology company pioneering next-generation targeted protein degradation approaches for cancer and other serious diseases, today announced...